目的:系统评价达拉非尼联合曲美替尼治疗黑色素瘤致皮肤不良反应的发生率。方法:计算机检索PubMed、EMbase、Cochrane Library、Web of Science和中国知网、维普、万方、中国生物医学文献数据库,收集国内外公开发表的相关研究,检索时间...目的:系统评价达拉非尼联合曲美替尼治疗黑色素瘤致皮肤不良反应的发生率。方法:计算机检索PubMed、EMbase、Cochrane Library、Web of Science和中国知网、维普、万方、中国生物医学文献数据库,收集国内外公开发表的相关研究,检索时间为自建库至2020年12月。采用Stata 15.1软件计算皮肤不良反应的发生率,采用Rev Man 5.3软件评估所有等级皮肤不良反应的相对危险度(RR)。结果:共纳入10项研究,2623例患者。Meta分析结果显示:达拉非尼联合曲美替尼治疗黑色素瘤致所有等级皮肤不良反应的发生率为:皮疹22%[95%CI(0.19,0.26)]、瘙痒10%[95%CI(0.08,0.11)]、角化过度7%[95%CI(0.04,0.10)]、脱发5%[95%CI(0.04,0.07)]、皮肤乳头状瘤1%[95%CI(0.01,0.03)]、痤疮样皮炎10%[95%CI(0.06,0.14)]、皮肤鳞状细胞癌2%[95%CI(0.00,0.04)]、干性皮肤10%[95%CI(0.08,0.12)]和红斑11%[95%CI(0.09,0.13)];与单用BRAF抑制剂相比,达拉非尼联合曲美替尼降低了瘙痒、角化过度、脱发、皮肤乳头状瘤、皮肤鳞状细胞癌的发生率(P<0.05)。结论:达拉非尼联合曲美替尼治疗黑色素瘤患者常见的皮肤不良反应为皮疹;与单用BRAF抑制剂相比,联合用药显著降低了皮肤不良反应的发生。展开更多
Drug hypersensitivity reaction (DHR) is defined as an immunologically mediated response to a pharmacology agent. Some reactions require prior sensitization and some do not. The interactions between different drugs and...Drug hypersensitivity reaction (DHR) is defined as an immunologically mediated response to a pharmacology agent. Some reactions require prior sensitization and some do not. The interactions between different drugs and the immune system occur by different mechanisms leading to variable clinical features. Some reactions are simple and do not alter patient quality of life. Some are life threatening and require immediate recognition and appropriate therapy. Confirming the diagnosis of DHR is often challenging. The environment in the Intensive care units (ICU) is considered high risk place for DHR development as it offers most of the risk factors. In this review, we offer a delicate combined approach that allows an accurate diagnosis of most of the DHRs encountered in the ICU.展开更多
文摘目的:系统评价达拉非尼联合曲美替尼治疗黑色素瘤致皮肤不良反应的发生率。方法:计算机检索PubMed、EMbase、Cochrane Library、Web of Science和中国知网、维普、万方、中国生物医学文献数据库,收集国内外公开发表的相关研究,检索时间为自建库至2020年12月。采用Stata 15.1软件计算皮肤不良反应的发生率,采用Rev Man 5.3软件评估所有等级皮肤不良反应的相对危险度(RR)。结果:共纳入10项研究,2623例患者。Meta分析结果显示:达拉非尼联合曲美替尼治疗黑色素瘤致所有等级皮肤不良反应的发生率为:皮疹22%[95%CI(0.19,0.26)]、瘙痒10%[95%CI(0.08,0.11)]、角化过度7%[95%CI(0.04,0.10)]、脱发5%[95%CI(0.04,0.07)]、皮肤乳头状瘤1%[95%CI(0.01,0.03)]、痤疮样皮炎10%[95%CI(0.06,0.14)]、皮肤鳞状细胞癌2%[95%CI(0.00,0.04)]、干性皮肤10%[95%CI(0.08,0.12)]和红斑11%[95%CI(0.09,0.13)];与单用BRAF抑制剂相比,达拉非尼联合曲美替尼降低了瘙痒、角化过度、脱发、皮肤乳头状瘤、皮肤鳞状细胞癌的发生率(P<0.05)。结论:达拉非尼联合曲美替尼治疗黑色素瘤患者常见的皮肤不良反应为皮疹;与单用BRAF抑制剂相比,联合用药显著降低了皮肤不良反应的发生。
文摘Drug hypersensitivity reaction (DHR) is defined as an immunologically mediated response to a pharmacology agent. Some reactions require prior sensitization and some do not. The interactions between different drugs and the immune system occur by different mechanisms leading to variable clinical features. Some reactions are simple and do not alter patient quality of life. Some are life threatening and require immediate recognition and appropriate therapy. Confirming the diagnosis of DHR is often challenging. The environment in the Intensive care units (ICU) is considered high risk place for DHR development as it offers most of the risk factors. In this review, we offer a delicate combined approach that allows an accurate diagnosis of most of the DHRs encountered in the ICU.
